- Home
- SYRS vs AIMD Comparison
SYRS vs AIMD Comparison
Compare SYRS & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRS
- AIMD
- Stock Information
- Founded
- SYRS 2011
- AIMD 1984
- Country
- SYRS United States
- AIMD United States
- Employees
- SYRS N/A
- AIMD N/A
- Industry
- SYRS Biotechnology: Pharmaceutical Preparations
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- SYRS Health Care
- AIMD Health Care
- Exchange
- SYRS Nasdaq
- AIMD Nasdaq
- Market Cap
- SYRS 7.1M
- AIMD 6.0M
- IPO Year
- SYRS 2016
- AIMD N/A
- Fundamental
- Price
- SYRS $0.20
- AIMD N/A
- Analyst Decision
- SYRS Hold
- AIMD
- Analyst Count
- SYRS 5
- AIMD 0
- Target Price
- SYRS $3.00
- AIMD N/A
- AVG Volume (30 Days)
- SYRS 2.4M
- AIMD 133.6K
- Earning Date
- SYRS 10-31-2024
- AIMD 11-06-2024
- Dividend Yield
- SYRS N/A
- AIMD N/A
- EPS Growth
- SYRS N/A
- AIMD N/A
- EPS
- SYRS N/A
- AIMD N/A
- Revenue
- SYRS $386,000.00
- AIMD $40,633.00
- Revenue This Year
- SYRS N/A
- AIMD N/A
- Revenue Next Year
- SYRS $1,011.11
- AIMD N/A
- P/E Ratio
- SYRS N/A
- AIMD N/A
- Revenue Growth
- SYRS N/A
- AIMD N/A
- 52 Week Low
- SYRS $0.18
- AIMD $0.40
- 52 Week High
- SYRS $8.17
- AIMD $4.29
- Technical
- Relative Strength Index (RSI)
- SYRS 29.55
- AIMD 44.50
- Support Level
- SYRS $0.20
- AIMD $0.43
- Resistance Level
- SYRS $0.22
- AIMD $0.50
- Average True Range (ATR)
- SYRS 0.02
- AIMD 0.04
- MACD
- SYRS 0.06
- AIMD 0.00
- Stochastic Oscillator
- SYRS 25.71
- AIMD 16.12
About SYRS Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.